TEL AVIV, Israel--(BUSINESS WIRE)--Feb. 26, 2004--Tissera, Inc. (OTCBB:TSSR - News), a biotechnology company dedicated to developing novel tissue precursor regeneration technologies to address a myriad of fatal illnesses where an organ transplantation is necessary announced today that the Editorial Board of Standard and Poor's ("S&P") approved Tissera Inc. for a complete corporate listing and description in the Standard and Poor's Corporation Records. Additionally, Tissera will have its corporate description published in Standard and Poor's Daily News Section. S&P also will initiate financial coverage of Tissera as part of the S&P Market Access Program, including coverage of Tissera on the S&P Internet site, www.advisorinsight.com, the S&P Marketscope and the electronic version of the S&P Stock Guide database. Additionally, S&P's coverage of Tissera will appear on the highly trafficked OTC Bulletin Board Internet site, www.otcbb.com.

Standard & Poor's Corporation Records is a recognized securities manual for the "Blue Sky" Standard Manual Exemption for secondary trading in more than 35 states. Tissera's listing in Standard & Poor's Corporation Records should assist the brokerage and investment communities in making a market for Tissera's stock. It is recommended that brokers check with their compliance officers or legal counsel for applicable "Blue Sky" laws and regulations pertaining to them.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera licensed the worldwide exclusive rights to the technology developed at the Weizmann Institute of Science in Israel led by Professor Yair Reisner. In this research, scientists successfully implanted embryonic human and porcine kidney precursor tissues in mice, which grew into functional kidneys. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."